Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Omapro Needs Companion Diagnostic, Advisory Committee Says

This article was originally published in The Pink Sheet Daily

Executive Summary

ChemGenex must determine which chronic myeloid leukemia patients have the T351I mutation and could benefit from the drug.

You may also be interested in...



Teva’s Synribo Clears FDA For Third-Line Chronic Myeloid Leukemia

Omacetaxine, which was originally submitted by ChemGenex as Omapro, demonstrated response rates of 14% to 18% in patients who had failed two or more tyrosine kinase inhibitors. It enters a crowded space that is likely to add a new member, Ariad’s ponatinib, in the coming months.

No Additional Omapro Trials Needed, FDA Tells ChemGenex In Complete Response Letter

FDA reservations mirror those outlined about need for validated assay test at March 22 ODAC meeting.

No Additional Omapro Trials Needed, FDA Tells ChemGenex In Complete Response Letter

FDA reservations mirror those outlined about need for validated assay test at March 22 ODAC meeting.

Topics

Latest News
UsernamePublicRestriction

Register

PS070391

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel